Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials - Wikidata - wikimedia - TriplyDB

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

http://www.wikidata.org/entity/Q28084309

about

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.Safety profile of biological therapies for treating rheumatoid arthritis.The role of IL-6 in host defence against infections: immunobiology and clinical implications.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.JAK inhibition in inflammatory bowel disease.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies.Tofacitinib: A Review in Rheumatoid Arthritis.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

P2860

Q26765028-C8D8B618-2A90-4B5E-AB97-BAB54E405D64 Q31158500-AC977878-F827-4E1B-97C9-BC6A11C4F788 Q33778719-AC29B091-CABF-4125-B848-C595AAD47C1B Q37662745-05C07EFB-E6F1-4FB5-ABB6-BD911CDE6924 Q38665700-1BE3B1E8-C291-4353-AC8D-07C6B59634DC Q38725223-97DB238F-C745-4361-A1B4-9E845AC78348 Q38751230-8260FAB0-EA17-4A4C-8FC8-4B365B869AE3 Q38761142-F97DCAA6-E87A-4B9F-9DE3-53BC85E9D5FB Q38761961-B09F4CD9-0F08-446F-BE73-8D771AF70381 Q38837769-63918781-7D8D-48A1-83B2-0DAD6A6615B6 Q39264020-12A7696B-5843-4F79-AAAC-3BBADA4C87BB Q39377679-A55B76BE-BD01-426B-9CDF-6F337F7C477C Q40267179-7AFC6FA5-8BB2-4503-8FAF-5FD735B1BD53 Q43280727-2F7F8963-925E-431B-B077-BD824885983D Q44581309-08566F7B-6910-4A12-9642-3CBD8411808B Q45804014-B0967047-1926-4DCF-9923-E7D574285035 Q47439880-2446BE7E-E41C-4B52-8E6C-D9793AE29425 Q48556502-6BB161C3-DFE0-403C-94DD-F3E8FB94E701 Q57245353-8B2FFCF8-E27F-47E0-A0B8-863B75EB9EEE Q58779800-F8E41D8E-462B-439C-A77A-85AC2DFE9D46

P2860

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

http://www.wikidata.org/entity/Q28084309

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Systematic review and meta-ana ...... toid arthritis clinical trials

@ast

Systematic review and meta-ana ...... toid arthritis clinical trials

@en

Systematic review and meta-ana ...... toid arthritis clinical trials

@nl

type

label

Systematic review and meta-ana ...... toid arthritis clinical trials

@ast

Systematic review and meta-ana ...... toid arthritis clinical trials

@en

Systematic review and meta-ana ...... toid arthritis clinical trials

@nl

prefLabel

Systematic review and meta-ana ...... toid arthritis clinical trials

@ast

Systematic review and meta-ana ...... toid arthritis clinical trials

@en

Systematic review and meta-ana ...... toid arthritis clinical trials

@nl

P1433

Q28084309-B61F486E-15B3-4ACF-A14A-FA4BFD14A36A

P1476

Q28084309-899D57D2-30D8-4C51-9AEF-4ABD759DA850

P2093

Q28084309-11311587-DD4C-4819-8053-AF3C008D67D5

Q28084309-1E7DE681-AC6C-42CE-9B0B-2AB98137F729

Q28084309-48E5AFBA-8976-4D37-996E-835242196E23

Q28084309-5D987774-DC80-4E20-AECF-5A8CA99F1467

Q28084309-633C9729-C64F-4ABB-BCED-F48AC62BD1C2

Q28084309-807CD6DD-550A-4FD3-958C-56AC72F2B04A

Q28084309-89EA46C7-6A6A-4285-9C2A-67B01ACC2265

Q28084309-B3D91CF0-2736-4268-83F4-5B3D8CD518B3

Q28084309-B9C16510-F510-4789-A4F6-C61CB9986B7F

Q28084309-C99C3DC5-DFAC-40F4-9AB9-FA05A7C57082

P275

Q28084309-E7707C19-18CB-4A98-BB07-F67EB2C744A9

P2860

Q28084309-026983FF-A756-4B55-811A-5C7F1C0BB003

Q28084309-1D859591-9704-4BC7-83B7-959C569DE073

Q28084309-3B5FDD3B-07D0-45FD-AE40-F4E5A3F87BF0

Q28084309-3F055AE9-E67D-4A4D-AD9B-DA28B4165DCE

Q28084309-4D31AF3B-D079-4BB3-9BA0-447E6045E7D7

Q28084309-52B3A21F-0407-4CAC-908A-9525A376A235

Q28084309-55206A8B-4384-4F27-8160-2EFA3544D340

Q28084309-5F001BBD-7ABF-434D-B22A-32B21080372C

Q28084309-76303F19-AE7A-4C4A-8C49-CE6D7F188CD0

Q28084309-9F1BF627-9061-4C66-9DF8-175C9CA1B653

P2888

Q28084309-B6E16F49-7ACC-497C-A8DE-D3C647848813

P304

Q28084309-D083C41F-9AD1-4C46-9183-1B39CCDA4A50

P31

Q28084309-099E2351-1A35-4756-8ECB-AF9B0C94AA83

Q28084309-44B35C9A-3A59-4326-A8B7-0CE6C6253C20

Q28084309-AF11E9E1-4F9F-4FEC-9821-6F406260B91F

Q28084309-B154C69D-A8AC-48BD-859A-D734D4BEC6E4

P356

Q28084309-8D52C776-71AA-4489-92D7-FE0B7A34DFBF

P407

Q28084309-8F503F20-E14E-4B3C-A5BE-1CAA3EFFBABF

P478

Q28084309-A52E7B06-45B7-4F3C-9407-EFC6778F2722

P5008

Q28084309-642285E9-021B-424B-99DA-5B487686371D

P577

Q28084309-335819FD-4BA1-4EEA-BC92-BD581427673E

P5875

Q28084309-775BED84-2258-4C0E-8485-36D1A39A172F

P6179

Q28084309-CD9D9A8F-FFA4-40F9-A0F7-5D7A9408841D

P698

Q28084309-6A52C33C-6B70-4D00-A35F-2DB13CE0FCA1

P921

Q28084309-3D9E618A-DE4D-459E-A628-EAE5C9794787

Q28084309-45B68791-2750-4863-9348-CF610874201C

Q28084309-B7EDE272-BE51-4DB8-9AAE-E61060236BD5

Q28084309-C496423B-FA19-4DD0-AFFF-897F2C575393

Q28084309-DF92932E-9C61-4A4A-9800-FB212A3EE60A

P932

Q28084309-556D4FAB-40C4-4D80-9FC7-902C8F9C9304

P356

S13075-015-0880-2

P1433

Arthritis Research and Therapy

P1476

Systematic review and meta-ana ...... toid arthritis clinical trials

@en

P2093

Elaine Hoffman

http://www.w3.org/2001/XMLSchema#string

Jamie Geier

http://www.w3.org/2001/XMLSchema#string

Jonathan French

http://www.w3.org/2001/XMLSchema#string

Juan J. Gómez-Reino

http://www.w3.org/2001/XMLSchema#string

Mary Boy

http://www.w3.org/2001/XMLSchema#string

Richard Riese

http://www.w3.org/2001/XMLSchema#string

Sima Ahadieh

http://www.w3.org/2001/XMLSchema#string

Sriram Krishnaswami

http://www.w3.org/2001/XMLSchema#string

Sujatha Menon

http://www.w3.org/2001/XMLSchema#string

Thomas G. Tensfeldt

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Bias in meta-analysis detected by a simple, graphical test

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Quantifying heterogeneity in a meta-analysis

Meta-analysis in clinical trials

Statistical aspects of the analysis of data from retrospective studies of disease

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

P2888

s13075-015-0880-2

P304

362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P356

10.1186/S13075-015-0880-2

http://www.w3.org/2001/XMLSchema#string

P407

P478

17

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287151814

http://www.w3.org/2001/XMLSchema#string

P6179

1037466384

http://www.w3.org/2001/XMLSchema#string

P698

26669566

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

rheumatoid arthritis

heterocyclic compound

P932

4704538

http://www.w3.org/2001/XMLSchema#string